CompletedNCT00206102
A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 62 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateSeptember 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,098
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00206102
- Official title
Show the full official title
A Multicenter, Open Label, Flexible-dose, Parallel-group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (Seroquel) and Risperidone (Risperdal) in the Long Term Treatment of Participants With Schizophrenia or Schizoaffective Disorder
Get this study by email
Recruitment & locations
CompletedLittle Rock · Mabelvale · Morrilton
60 more locations
- Anaheim
- Cerritos
- Chula Vista
- Garden Grove
- Long Beach
- Los Angeles
- Orange
- San Diego
- San Marcos
- Denver
- New Britian
- Boca Raton
- Boynton Beach
- Deerfield Beach
- Fort Lauderdale
- Orlando
- Pompano Beach
- Tampa
- West Palm Beach
- Atlanta
- Augusta
- Chicago
- Joliet
- Oak Brook Terrace
- Schaumburg
- Newton
- Wichita
- Metairie
- New Orleans
- Glen Burnie
- Minneapolis
- St Louis
- Las Vegas
- Cherry Hill
- Moorestown
- Paramus
- Stratford
- Brooklyn
- New York
- Staten Island
- Beechwood
- Cincinnati
- Dayton
- Lyndhurst
- Medina
- Oklahoma City
- Portland
- Media
- Philadelphia
- Charleston
- Austin
- Dallas
- Houston
- Irving
- McKinney
- San Antonio
- Midvale
- Arlington
- Falls Church
- Richmond
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including quetiapine fumarate and risperidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia